Amicogen, Inc Company Profile
>
Amicogen, Inc.
Pharmaceuticals
- Type
Public
- Headquarters
South Korea
- Establishment
2000
- Key Management
Mr.Yong-Chul Shin (CEO)
- Revenue
~104.9 (2021)
- Headcount
~182 (2021)
- Website
Business Description
Amicogen, Inc. specializes in developing, selling, and functional food materials and marketing enzyme products. The company’s products include specialty enzymes that can be used in pharmaceuticals, food, and feed as well as immunological products like the protein A resin and new bio-ingredients such as natural health ingredients for food or feed.
Key Financials
Revenue (US$ Mn):
- Amicogen, Inc’s annual revenue for 2021 was US$ 105 Mn, a 7.48% increase from 2020
- The annual revenue generated by Amicogen, Inc in 2020 was US$ 98 Mn
Operating Income (US$ Mn):
- US$ 3 Mn was Amicogen, Inc’s operating income in 2021, a -247.37% decrease from 2020 figures
- Amicogen, Inc indexed a -195% decrease in operating incomes from 2019, amounting to US$ -2 Mn in 2020
- Amicogen, Inc generated an operating income of US$ 2 Mn in 2019
Net Income (US$ Mn):
- US$ 29 Mn was the net income generated by Amicogen, Inc in 2021
- Amicogen, Inc’s net income for 2020 was US$ Mn, a -100.54% decrease from 2019
Operating Margin %:
- The operating margin generated by Amicogen, Inc in 2020 was %
Gross Margin %:
- 39% was Amicogen, Inc’s gross margin in 2021, a -7.84% decrease from 2020 figures
- Amicogen, Inc indexed a 30.34% increase in gross margins from 2019, amounting to 42% in 2020
- Amicogen, Inc generated a gross margin of 32% in 2019
SWOT Analysis
Strengths
Get this premium content
The Premium data is Locked
✖